Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-Transplant Cyclophosphamide for GVHD Prophylaxis
NCT01749111Phase 3Terminated
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Dec 2012
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Hospital Israelita Albert Einstein. Started Dec 2012; status: terminated.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01749111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01749111.